This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drugdevelopers may need to reassess their therapeutic strategies. This has led drugdevelopers to unintentionally limit their potential within chosen therapeutic spaces.
In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drugdevelopers for phase I trials, second only to navigating regulatory compliance (- 38 percent). Silver Spring (MD): Food and Drug Administration (US); 2016-. Bagyinszky E, et al. 21(10):3517.
Generative artificial intelligence (AI) has captured global attention for its transformative potential across industries, and nowhere is the promise greater — or more fraught — than in health care and clinicalresearch. Accelerate your clinicalresearch with our drugdevelopment digital solutions from Thermo Fisher Scientific.
As a result, drugdevelopers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Accelerate customer speed to market With a modern and integrated user experience, AI solutions put the right data and insights into the right hands in real time.
1] It’s a privilege to participate in such a prestigious gathering of vision science professionals, and to gain insight into the latest innovations and treatments for complex ocular diseases. These technologies are helping pave the way toward more objective, reliable tools for clinicalresearch. conference locations.
Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drugdevelopment. I opted for medicine due to my love for biological sciences.
Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. In this interview, Bagnall explains how this approach is improving patient outcomes and driving the development of better obesity drugs. Mark is an entrepreneur and business manager in the healthcare industry.
It takes a family to develop a drug Trembles role at Poolbeg is multifaceted, reflecting the collaborative ethos of the companys scientific team. I take responsibility for identifying pre-clinicalresearch that can support our clinical programs, as well as designing and overseeing its execution, he explains.
The complexity of diagnosing IPF, understanding its root causes, and translating preclinical findings to clinical success make it a challenging disease for drugdevelopment. However, recent advancements and strategic approaches in clinical trials offer hope that additional treatments are on the way. Ready to connect?
In an era where science and technology are surpassing what was ever thought possible, the need for the biotech industry to adapt, respond and evolve as quickly and cost efficiently as possible is more urgent than ever. Many biotechs pour resources into assembling full teams and facilities, only to face setbacks that stall progress.
To that end, the PI can ensure patients understand the science of appetite and metabolic regulation, for example, to relieve some of the self-imposed expectations for instant weight loss or other quick signs of success. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.
Artificial Intelligence (AI) imitates human cognitive functions using computer science, algorithms, machine learning and data sciences. AI can analyze large volumes of data from interventional and non-interventional studies to draw conclusions about a drug’s safety and effectiveness quicker than humans.
5 Organoids are recognised as New Alternative Methods (NAMs) in drugdevelopment. This recognition was codified by the United States Food and Drug Administration (FDA) in 2022 with the signing of the FDA Modernisation Act 2.0 This can aid in the development of safer, more effective therapeutic strategies.
With so many exciting developments in the last few years, it’s critical for the psychedelic community to come together to reflect on our progress, share the latest discoveries, and discuss the future of psychedelic research. Check out our full psychedelics offering, and meet the team responsible for planning your clinical trial.
Acceleration in every step of clinicalresearch is critical to pharmaceutical developers. Yet, today’s clinicalresearch sponsors face significant challenges. These delays financially disrupt the potential of both current and future clinicalresearch. With a median delay of 12.2
By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drugdevelopment process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.
By: Sarah Bly and Aman Khera, Regulatory Science and Innovation The journey of bringing a new therapeutic agent from the laboratory to the marketplace is fraught with challenges, not least of which is navigating the complexities of regulatory feedback, which do not always converge but can diverge.
By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during the drugdevelopment process should companies start to engage these key stakeholders?
Listen to the audiobook >>> Issue 33 — CNS DrugDevelopment: Integrated Solutions Lessen Complexity Hear about the complexities of CNS drugdevelopment programs and how an integrated CRO/CDMO can help move your molecule seamlessly from one phase to the next. Listen to the audiobook >>> Image Social Media Promo-01.jpg
As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drugdevelopment shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the DrugDevelopment Industry in 2024 1.
Despite a rapidly evolving clinicaldevelopment landscape, we’ve remained grounded in medicine and science, helping sponsors achieve their clinicaldevelopment goals across a range of therapeutic areas through our ability to adapt to changing client needs, deliver customized study teams, and dedicated scientific expertise.
Yet, four out of five care partners of people with neurodegenerative disorders have never been informed of clinical trial opportunities , according to a survey of more than 250 caregivers conducted by PPD, the clinicalresearch business of Thermo Fisher Scientific. There’s little time to lose.
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity. This convergence of trials, labs and data sciences is driving faster clinicaldevelopment and approval.
Top 10 Life Science Resources pmjackson Tue, 07/18/2023 - 19:01 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. There are several reasons why choosing Canada for your clinical trials can be beneficial.
As my experience in preclinical research grew, so did my curiosity in the overall drugdevelopment process; I wanted to expand into clinicalresearch. Following that realization, I switched my goals to science, biology, and health, and started down my current career path. What Was your dream job as a child?
The SCOPE (Summit for Clinical Ops Executives) conference is a premier event in the field of clinical operations, providing a comprehensive platform for professionals to explore the latest trends and innovations in clinicalresearch. Are you attending SCOPE? Reach out to connect with us.
From a very young age, I was drawn to science and medicine. This early exposure to bench science had a long-lasting impact. Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drugdevelopment.
The Sustainable Healthcare Coalition , a not-for-profit, health care sector-led group based in the United Kingdom, concluded that globally, clinicalresearch could generate the equivalent of 100 million tons of carbon dioxide (CO2) emissions each year.
The Sustainable Healthcare Coalition , a not-for-profit, health care sector-led group based in the United Kingdom, concluded that globally, clinicalresearch could generate the equivalent of 100 million tons of carbon dioxide (CO2) emissions each year.
The advent of outsourcing in clinicalresearch came about in the 1980s based on transactional business-to-business interactions, which focused on the completion of specific development tasks. Instead, a CRO offering consultative services and strategic development elevates the full development program.
The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinicalresearch. The Impact of Draft Guidance on DrugDevelopment As it stands, drugdevelopment is an expensive endeavor, costing approximately $2.3
With the necessary prioritization of various factors when designing your clinical trial, the patient experience can be overlooked or improperly addressed in study design. However, incorporating the patient experience into your design is one of the best ways to ensure your drugdevelopment program is a commercial success.
Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinicalresearch and development at companies across Europe and the US. Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe.
Through the years, NIH has supported a total of 169 researchers who have received or shared 101 Nobel Prizes. That’s quite a testament to the world-leading science that NIH pursues and its continued impact on improving human health and well-being. Science 2008, 320 (5876), 664–667. [6] For Carolyn R. 2004 Jul;11(7):1009-1016.
Altasciences Receives 2024 CRO Leadership Award for Capabilities aasimakopoulos Wed, 05/29/2024 - 17:54 Laval, Québec, May 29, 2024 – Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities.
Contract research organizations (CROs) are an integral partner of the drugdevelopment process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?
The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drugdevelopers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.
To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drugdevelopment and regulatory pathways and to run clinical trials. As von Itzstein et al.
As clinical trials grow more complex and data-intensive, addressing these pain points in data management becomes increasingly crucial for researchers and product teams. A Unified Clinical Trial Data Management Platform Life sciences leaders are engaging our industry experts to reimagine the clinical data review process.
However, over the past decade, a trend toward incorporating multiple study populations into one protocol has slowly gathered momentum among drugdevelopers. Improved prioritization Promising pipeline candidates with a strong early development protocol may see a positive impact to the net present value of an early-stage asset.
Breaking the Barriers: How Inaccurate Trial Records Are Delaying DrugDevelopment and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.
Irena Seredina holds a Medical Doctor, honors diploma and a Master of Science degree in Health Economics. During her medical practice, Seredina worked in clinicalresearch as an investigator. He has worked for a number of partner research organizations in clinicaldevelopment, including Biotrial, Celerion and Parexel.
Their passion and curiosity to expand the boundaries of toxicology research illuminated the room. As experts in early-phase drugdevelopment , from discovery through Phase II clinicalresearch , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists.
These anecdotal struggles were highlighted in industry research conducted by PPD, the clinicalresearch business of Thermo Fisher Scientific. In a survey of more than 150 global drugdevelopment leaders, more than a quarter (28%) cited lack of R&D funding as the top challenge facing their organization.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content